株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Chong Kun Dang Pharmaceutical Corp.:製品パイプライン分析

Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224658
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
Chong Kun Dang Pharmaceutical Corp.:製品パイプライン分析 Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 63 Pages
概要

Chong Kun Dang Pharmaceutical Corp.は、バルク薬を始め、処方薬、市販薬、また、ビタミン、シャンプー、ヘアカラー、エアゾール、マット気化器、蚊取線香などの製品を製造し、卸し、輸出入している製薬会社です。同社の中央研究所では、腫瘍学、免疫学、心血管、代謝性疾患、感染症、、中枢神経系疾患、呼吸器疾患の領域における治療薬の研究、化学的研究、および新薬の開発に取り組んでいます。

当レポートでは、Chong Kun Dang Pharmaceutical Corp.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Chong Kun Dang Pharmaceutical Corp.の基本情報

Chong Kun Dang Pharmaceutical Corp.の概要

  • 主要情報
  • 企業情報

Chong Kun Dang Pharmaceutical Corp. :R&Dの概要

  • 主な治療範囲

Chong Kun Dang Pharmaceutical Corp. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Chong Kun Dang Pharmaceutical Corp. :パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Chong Kun Dang Pharmaceutical Corp. :薬剤プロファイル

  • beloranib
  • carvedilol SR
  • CKD-943
  • (amlodipine besylate + candesartan)
  • CKD-941
  • CKD-942
  • CR-845
  • LT-0011
  • CKD-12101
  • CKD-12201
  • CKD-516
  • CKD-519
  • CKD-581
  • CKD-902
  • CKD-903
  • darbepoetin alfa
  • CKD-10101
  • CKD-830
  • CKD-841
  • Drug to Inhibit HDAC6 for Rheumatoid Arthritis
  • Nepodin

Chong Kun Dang Pharmaceutical Corp. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Chong Kun Dang Pharmaceutical Corp. :最近のパイプライン動向

Chong Kun Dang Pharmaceutical Corp. :休止中のプロジェクト

Chong Kun Dang Pharmaceutical Corp. :本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08200CDB

Summary

Global Markets Direct's, 'Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016', provides an overview of the Chong Kun Dang Pharmaceutical Corp's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Chong Kun Dang Pharmaceutical Corp
  • The report provides overview of Chong Kun Dang Pharmaceutical Corp including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chong Kun Dang Pharmaceutical Corp's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chong Kun Dang Pharmaceutical Corp's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Chong Kun Dang Pharmaceutical Corp's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chong Kun Dang Pharmaceutical Corp
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chong Kun Dang Pharmaceutical Corp's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chong Kun Dang Pharmaceutical Corp Snapshot
    • Chong Kun Dang Pharmaceutical Corp Overview
    • Key Facts
  • Chong Kun Dang Pharmaceutical Corp - Research and Development Overview
    • Key Therapeutic Areas
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products Glance
    • Chong Kun Dang Pharmaceutical Corp - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chong Kun Dang Pharmaceutical Corp - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chong Kun Dang Pharmaceutical Corp - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Chong Kun Dang Pharmaceutical Corp - Drug Profiles
    • (amlodipine besylate + candesartan cilexetil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (atorvastatin calcium + choline fenofibrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (atorvastatin calcium + ezetimibe) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lobeglitazone + metformin hydrochloride XR) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (tadalafil + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-516 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-581 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • difelikefalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hyaluronate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levocabastine hydrochloride + mometasone furoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nepodin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Analysis
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Target
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Route of Administration
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Molecule Type
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action
  • Chong Kun Dang Pharmaceutical Corp - Dormant Projects
  • Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • beloranib
  • Chong Kun Dang Pharmaceutical Corp - Company Statement
  • Chong Kun Dang Pharmaceutical Corp - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chong Kun Dang Pharmaceutical Corp, Key Facts
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Indication, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
  • Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Combination Treatment Modalities in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase III, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase II, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase I, 2016
  • Chong Kun Dang Pharmaceutical Corp - Preclinical, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Target, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action, 2016
  • Chong Kun Dang Pharmaceutical Corp - Dormant Developmental Projects,2016
  • Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products, 2016
  • Chong Kun Dang Pharmaceutical Corp, Other Locations

List of Figures

  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Indication, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
  • Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Target, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top